A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Crohn's Disease
Спонсор: Janssen Research & Development, LLC
Налично на:
БГ
Обобщение
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Кой може да участва
Inclusion Criteria:
* Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline
* Confirmed diagnosis of moderate to severe CD as assessed by Crohn'
Места на провеждане
32
Австралия (1)
The Queen Elizabeth Hospital
Adelaide
Белгия (1)
GZA Ziekenhuizen
Antwerp
Бразилия (1)
Hospital Das Clinicas Da Ufmg
Belo Horizonte - MG
България (1)
UMHAT 'Aleksandrovska' EAD
Sofia
Канада (1)
Foothills Hospital
Calgary , Alberta
Китай (1)
China Japan Friendship Hospital
Beijing
Хърватия (1)
Opca bolnica Bjelovar
Bjelovar
Чехия (1)
Vojenska nemocnice Brno
Brno
Дания (1)
Aarhus University Hospital
Aarhus
Estonia (1)
West Tallinn Central Hospital
Tallinn
Франция (1)
CHU Amiens - Hopital Sud
Amiens
Гърция (1)
General Hospital of Athens 'Ippokrateion'
Athens
Унгария (1)
Obudai Egeszsegugyi Centrum Kft
Budapest
Индия (1)
ICON Hospital Orchid Medi services and Research Private Limited
Ahmedabad
Израел (1)
Haemek Medical Center - Afula
Afula
Италия (1)
Università degli Studi di Bari
Bari
Япония (1)
Asahikawa Medical University Hospital
Asahikawa
Jordan (1)
Jordan University Hospital
Amman
Malaysia (1)
Hospital Sultanah Bahiyah
Alor Star
Нидерландия (1)
Academisch Medisch Centrum Universiteit van Amsterdam
Amsterdam
New Zealand (1)
Dunedin Hospital
Dunedin
Норвегия (1)
Alesund sjukehus
Ålesund
Полша (1)
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
БГ
EN